Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Stentoft

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
European Journal of Haematology|August 21, 2021
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 studyHjalmar Flygt, Stina Söderlund, Jesper Stentoft, et al.
Acta Oncologica (Stockholm, Sweden)|September 1, 2023
Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort studyLise Skovgaard Svingel, Sarah Friis Christensen, Anders Kjærsgaard, et al.
European Journal of Haematology|July 28, 2022
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort studySarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjaersgaard, et al.
Ugeskrift for Laeger|October 28, 2021
[Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases]Hans Carl Hasselbalch, Trine Alma Knudsen, Anders Lindholm Sørensen, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Journal of Blood Medicine|June 12, 2025
Thrombotic Thrombocytopenic Purpura and Evans Syndrome: Validating and Exploring 20 Years of Routine Hospital CareDana Audrey Lawrie, Dennis Lund Hansen, Thomas Leineweber Kristensen, et al.
Acta Haematologica|May 5, 2005
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-upBengt Simonsson, Gunnar Oberg, Mats Bjoreman, et al.
The Journal of Clinical Investigation|September 1, 2022
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemiaJani Huuhtanen, Mette Ilander, Bhagwan Yadav, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
European Journal of Haematology|August 21, 2021
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 studyHjalmar Flygt, Stina Söderlund, Jesper Stentoft, et al.
Acta Oncologica (Stockholm, Sweden)|September 1, 2023
Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort studyLise Skovgaard Svingel, Sarah Friis Christensen, Anders Kjærsgaard, et al.
European Journal of Haematology|July 28, 2022
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort studySarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjaersgaard, et al.
Ugeskrift for Laeger|October 28, 2021
[Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases]Hans Carl Hasselbalch, Trine Alma Knudsen, Anders Lindholm Sørensen, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Journal of Blood Medicine|June 12, 2025
Thrombotic Thrombocytopenic Purpura and Evans Syndrome: Validating and Exploring 20 Years of Routine Hospital CareDana Audrey Lawrie, Dennis Lund Hansen, Thomas Leineweber Kristensen, et al.
Acta Haematologica|May 5, 2005
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-upBengt Simonsson, Gunnar Oberg, Mats Bjoreman, et al.
The Journal of Clinical Investigation|September 1, 2022
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemiaJani Huuhtanen, Mette Ilander, Bhagwan Yadav, et al.
Pageof 4